ESWT vs Orthosis in Trigger Finger
Launched by AZIENDA OSPEDALIERO-UNIVERSITARIA CONSORZIALE POLICLINICO DI BARI · Dec 12, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different treatments for a condition called trigger finger, which causes pain and difficulty in bending the fingers. The researchers want to compare the effects of Extracorporeal Shock Wave Therapy (ESWT), a non-invasive treatment that uses sound waves to promote healing, with the use of an orthosis, a type of supportive device that can help keep the finger in a stable position. Previous studies have shown that ESWT can be effective, and this trial aims to see how it stacks up against wearing an orthosis for patients with trigger finger.
To be eligible for this trial, participants must be aged 65 to 74 and have a grade 2 or 3 trigger finger that has been bothering them for at least three months. However, those who have had recent treatments like physical therapy or injections, or have certain medical conditions, will not be able to participate. If you join the study, you can expect to receive one of the treatments and be followed up for improvements over the next six months. This is a great opportunity to help researchers learn more about effective treatments for trigger finger and potentially benefit from new therapies.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Grade 2\~3 trigger finger according to Quinnell classification
- • problem that has been occurring for at least 3 months
- Exclusion Criteria:
- • Previous treatment via physiotherapy, local corticosteroid injection or surgical release for trigger finger within 3 months prior to recruitment.
- • Presence of musculoskeletal disease or previous nerve injury to the upper extremities.
- • Multiple trigger finger.
- • contraindications to treatment with ESWT: local infection; epilepsy; malignant tumor; inflammatory arthritis; cardiac arrhythmia or cardiac pacemaker; and pregnancy.
About Azienda Ospedaliero Universitaria Consorziale Policlinico Di Bari
The Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari is a prominent healthcare institution in Italy, dedicated to advancing medical research and clinical excellence. As a leading clinical trial sponsor, it integrates hospital and university resources to foster innovative research initiatives aimed at improving patient care and treatment outcomes. The institution is committed to upholding the highest ethical standards in clinical trials, ensuring rigorous scientific methodologies and patient safety. With a multidisciplinary approach, the Policlinico di Bari collaborates with various academic and research organizations, positioning itself at the forefront of medical discovery and healthcare advancement.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Giuseppe Solarino, M.D.
Study Director
University of Bari
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported